Follow Philip Morris to never miss an important update.
Philip Morris is scheduled to report its quarterly results on Wednesday, October 21. Analysts expect the company to bring in about 11.28 billion dollars in revenue and earn roughly 2.30 dollars per share. For a long-term owner, the most important numbers will be the growth of ZYN nicotine pouches and IQOS devices. The company is trying to move its business away from traditional cigarettes, and these smoke-free products now make up nearly 40 percent of its total sales. This report will show if that transition is still on track.
UBS raised its price target for Philip Morris from $182 to $192 but kept its rating at neutral. This move suggests the firm sees the stock as fairly valued at its current price rather than a bargain to buy right now. The average target across all analysts remains higher at $212. While the company is successfully shifting toward smoke-free products like ZYN and IQOS, this specific update reflects a view that much of that progress is already reflected in the stock's recent price.
Source: UBS
The U.S. Food and Drug Administration is expected to announce new measures to shorten the approval time for nicotine pouches and vaping products. Currently, the process for getting a new nicotine product authorized for sale in the U.S. can take years and involves thousands of pages of data.
This is a helpful development for Philip Morris as it works to expand its smoke-free business in the U.S. market. The company is currently scaling up its ZYN nicotine pouches and preparing to launch its IQOS heat-not-burn devices. A faster, more predictable path to approval would make it easier for the company to bring newer versions of these products to American shelves.
Source: Reuters
The board raised the quarterly dividend to $1.60 per share, up from $1.47. This increase will be paid out in late October to anyone who owns the stock as of October 2.
For a company like Philip Morris, these annual raises are a key part of why people own the stock. It shows management is confident that the shift toward smoke-free products like ZYN and IQOS is generating enough steady cash to keep rewarding shareholders even as traditional cigarette volumes fall.
Source: Business Wire
Philip Morris is expanding its Zyn lineup and adding more nicotine pouches to each can. This move follows a summer of heavy spending on new factories and a favorable ruling from regulators that cleared the way for more growth in the U.S. market.
Zyn is the fastest-growing part of the business, and the company is using its scale to make the product more attractive to customers. By increasing the pouch count, Philip Morris is making it harder for smaller rivals to compete on value while it works to shift its revenue away from traditional cigarettes.
Source: WSJ
Management consistently sets a bar they can clear, having topped analyst profit targets for eight straight quarters. This track record suggests the business is growing even faster than their own forecasts.
| Expectation | |
|---|---|
| EPS | $2.30 |
| Revenue | $11.28B |
Follow Philip Morris to get the latest and most important updates.
Follow PM